top of page
BOOK COMERCIAL - II SIMPÓSIO NACIONAL DE IMUNOTERAPIA (3).png
Fundo gradiente azul

December 1st to 3rd, 2026
Porto Alegre/RS

The III National Immunotherapy Symposium is a unique event that brings together professionals from different areas of health to discuss the latest trends and advances in immunotherapy with a focus on oncology and precision medicine.

HOT TOPICS

  • CAR-T cells

  • Flow Cytometry

  • ​Transcriptomics

  • Single-cell and spatial 

Fundo gradiente azul

Venue

Federal University of Health Sciences of Porto Alegre (UFCSPA)
 

Sarmento Leite, 245,  CEP: 90050-170
 

Building 2, third floor, Moacyr Scliar Theater

BOOK COMERCIAL - II SIMPÓSIO NACIONAL DE IMUNOTERAPIA (4).png

Program

DATE: 01/12/2026

10:00 - Flow Cytometry Course: Sponsored course on Advances in Flow Cytometry

12:00 - Course: Immunotherapy Technologies: Training course on Immunotherapy Technologies

14:00 - Immunotherapy for patients, families and the community in general: Round table with doctors explaining the rationale of immunotherapy in accessible language

17:00 - Official Opening: Opening lecture (speaker to be defined)


DATE: 02/12/2026

09:00 - Cellular Immunotherapies: Round table on CAR-T cell therapies in different treatments

12:00 - Transcriptomics Course: Sponsored course on single-cell and spatial transcriptomics technologies

14:00 - Antibodies for Immunotherapy: Presentations on new antibodies in immunotherapy by researchers and young talents

16:00 - Identification of New Targets and Response Markers for Immunotherapies: Lectures on advances in new targets and markers

5:30 PM - Poster Session: Poster session and networking

DATE: December 3, 2026

9:00 AM - Ongoing Clinical Studies: Roundtable discussion with presentation of results from clinical trials with immunotherapy

11:30 AM - Meeting between startups and venture capitalists: Debate on promising projects for investment in biotechnology

1:00 PM - Closing: Closing session

Submission Rules

Submission deadline: To be announced
Results announcement: To be announced


RESPOND TO GOOGLE FORM, LINK BELLOW - To be announced

Submission rules

  • Presentations could be in Portuguese or English;

  • Submit references separately from the abstract;

  • Abstract in accordance with ABNT;

  • References in the abstract must be restricted to a minimum, only numbers;

  • Abstracts must not exceed two thousand (2,000) characters, including spaces;

  • Abstract titles must not exceed 255 characters, including spaces;

  • The names, e-mails, CPF (only for Brazilians), passport numbers and affiliations of all authors must be included in the abstract submission form;

  • Abbreviations must be defined when they are mentioned for the first time in the abstract;

  • Abstracts must not contain tables, graphs or images.

 

Any questions, please send an email: lab.imunoterapia@gmail.com
Please name the email subject as:
"III National Immunotherapy Symposium -  Abstract Subimission"

Evaluation Criteria

  • Presentations could be in Portuguese or English;

  • All approved abstracts must be accompanied by the respective presentation in poster format. The poster must be presented, obligatorily, by the author responsible for submitting the abstract (PRESENTER), at the time and place established by the event organizers;

  • The presentations will be evaluated by an independent committee, based on the following criteria:

    • Relevance of the topic

    • Originality and innovation

    • Clarity and objectivity in the presentation

    • Methodological and scientific quality of the research

    • Conclusions and contributions to the field of knowledge​

BOOK COMERCIAL - II SIMPÓSIO NACIONAL DE IMUNOTERAPIA (4).png

Support

Organized by

Design sem nome (7)_edited.jpg

Phone

(51) 3303-8874

Contacts

Social Media

  • Instagram
  • LinkedIn

Funding Agencies for LAIT

logo cnpq
logo pronon projetos
logo projeto rites
logo ministerio da saude brasil
logo fapergs
logo capes brasil
logo santa casa

©2023 por Laboratório de Imunoterapia - UFCSPA

Site Visitors (All views):

bottom of page